决奈达隆治疗心房颤动相关临床研究与药物经济学研究进展
World Clinical Drugs(2020)
Abstract
心房颤动(atrial fibrillation,AF)是临床常见心律失常之一,其可并发血栓栓塞、卒中(stroke)等并发症,严重威胁患者生命.决奈达隆(dronedarone)是近十年来惟一获批上市的、用于长期节律控制的新型抗心律失常药物.本文就国内、外AF患者应用决奈达隆的临床效果及经济学评价进行综述,以期为临床应用决策和医保等相关卫生政策制定提供参考.
MoreAI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined